X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.
Lead Product(s): Emactuzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: SynOx Therapeutics
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 22, 2024
Details:
Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Idelalisib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CAL101
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Calluna Pharma
Deal Size: $81.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 22, 2024
Details:
Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
Lead Product(s): KYN-5356
Therapeutic Area: Neurology Product Name: KYN-5356
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Kynexis Therapeutics
Deal Size: $62.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 07, 2023
Details:
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and seizures in TSC.
Lead Product(s): Basimglurant
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Noema Pharma
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 07, 2023
Details:
The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infections.
Lead Product(s): Olorofim
Therapeutic Area: Infections and Infectious Diseases Product Name: F901318
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: F2G Limited
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 04, 2022
Details:
Proceeds will fund further clinical development of its lead asset, ARM210, for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) as well as other cardiac and skeletal muscle indications.
Lead Product(s): ARM210
Therapeutic Area: Genetic Disease Product Name: S48168
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ARMGO Pharma
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 20, 2021
Details:
Proceeds from this financing will enable the Company to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. ANV419, is designed to signal through the IL-2 beta/gamma receptor and overcome known challenges of human IL-2.
Lead Product(s): ANV419
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Anaveon
Deal Size: $119.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2021
Details:
PJS-539 is a potent, once daily, oral pill that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses to treat COVID-19.
Lead Product(s): PJS-539
Therapeutic Area: Infections and Infectious Diseases Product Name: PJS-539
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
